We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. ImmunityBio, Inc. is among the best biotech stocks. TheFly reported on January 20 that Piper Sandler raised its price target on IBRX to $7 from $5 and maintained an Overweight rating. According to the update, U.S. ANKTIVA net sales increased by almost 700% year over year to $113 million in 2025. Revenue is expected to reach $180 million in 2026. A possible label expansion for ANKTIVA in 2027 may be supported by positive QUILT- ...

We recently published 10 Big Names With Painful Declines. ImmunityBio Inc. (NASDAQ:IBRX) was one of the worst performers on Tuesday. ImmunityBio extended losses for a third day on Tuesday, shedding 4.19 percent to close at $5.95 apiece as investors continued to take profits after recording 14 straight days of gains last week. For the entire month of January until Thursday, January 22, ImmunityBio Inc. (NASDAQ:IBRX) has already soared by 271 percent following a flurry of positive developments, including ...

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether ImmunityBio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Jan ...

ImmunityBio (NASDAQ:IBRX), an immunity-focused biotech, closed Friday’s session at $6.45, down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month. Trading volume reached 74.6 million shares, coming in about 238% above its three-month average of 22.1 million shares. ImmunityBio IPO'd in 2015 and has fallen 83% since going public. How the markets moved today The broader markets were relatively steady Friday, with the S&P 500 (SNPINDEX:^GSPC) edging up 0.03% to 6,915 a ...

Company Overview - ImmunityBio, Inc. (NASDAQ:IBRX) develops therapies aimed at enhancing the immune system to combat infectious diseases and various cancers [2]. Stock Performance - The stock has experienced significant gains, with an increase of over 130% since a recent comment was aired, and a year-to-date rise of over 220% [3]. Analyst Opinions - Jim Cramer expressed skepticism about ImmunityBio, indicating that the company has been unprofitable for an extended period and does not favor the stock as a good investment [2]. - Cramer suggested that investors should consider taking profits on the stock due to its substantial price increase following an FDA meeting [1]. Investment Comparison - While acknowledging the potential of IBRX, it is noted that certain AI stocks may present greater upside potential and lower downside risk compared to ImmunityBio [3].

On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock.NASDAQ : IBRXImmunityBioToday's Change( 6.79 %) $ 0.44Current Price$ 6.92Key Data PointsMarket Cap$6.4BDay's Range$ 5.71 - $ 7.1052wk Range$ 1.83 - $ 7.98Volume96MAvg Vol19MGross Margin80.41 %ImmunityBio (IBRX +6.79%), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what ...

Key Takeaways IBRX surged 17.4% after FDA talks aligned on the regulatory path for Anktiva in papillary NMIBC.ImmunityBio finished the requested analyses and plans an sBLA resubmission within a month, with no new study.IBRX's QUILT-3.032 study (Cohort B) met its endpoint, showing durable clinical efficacy with Anktiva.Shares of ImmunityBio (IBRX) surged 17.4% after it announced a recent face-to-face meeting with senior FDA officials to align on the regulatory path forward for Anktiva in an additional indica ...

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label expansion in bladder cancer, and investors are watching next steps on the planned data resubmission path. Trading volume reached 209.3 million shares, about 1,000% above its three-month average of 19.1 million shares. ImmunityBio IPO'd in 2015 and has fallen 81% since going public. How the markets moved today ...

ImmunityBio Inc. (NASDAQ:IBRX) on Tuesday said it plans to submit additional information to the U.S. Food and Drug Administration (FDA) within 30 days following a Type B end-of-phase meeting related to its supplemental biologics license application for Anktiva in papillary non-muscle invasive bladder cancer (NMIBC).The stock is trading higher with a session volume of 178.91 million versus the average volume of 15.9 million, as per data from Benzinga Pro.The company said the FDA provided feedback during disc ...